3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
7
Burkitt Lymphoma
5
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Extranodal NK-T-Cell
2
Neoplasm, Residual
1
Lymphohistiocytosis, Hemophagocytic
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Down Syndrome
1
Interventions
Cyclophosphamide
7
venetoclax
6
Azacitidine
6
fludarabine
5
Cytarabine
4
Blood Specimen Collection
4
daratumumab
3
Lenalidomide
3
Daunorubicin
3
tislelizumab
2
fludarabine phosphate
2
Rituximab
2
Liquid Biopsy
2
Idarubicin
2
Gemtuzumab
2
Capecitabine
2
Busulfan
2
trastuzumab deruxtecan
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
tagraxofusp
1
sugemalimab
1
sacituzumab govitecan
1
relugolix
1
pembrolizumab
1
pegaspargase
1
palbociclib
1
obinutuzumab
1
ivosidenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasm, Residual
×
pegaspargase
×
Clear all
NCT05959720
2025-05-07
BRALLA
Instituto do Cancer do Estado de São Paulo
Recruiting
180 enrolled